



April 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2015-000590-12/ Novartis Protocol ID CRAD001HDE53

A 36 month multi-center, open-label, randomized, controlled study to evaluate the evolution of renal function in maintenance liver transplant recipients receiving either RAD001 (Everolimus) plus reduced CNIs or RAD001 (Everolimus) plus MPA.

Trial CRAD001HDE53 was cancelled with no patient enrollment and as such, no results will be reported.